Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03895372 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
NCT03895372 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 179 participants.
The verdict
NCT03895372, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
Study Summary
This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical development of PF-06826647.
Interventions
- DRUG PF-06826647 or Placebo
- DRUG PF-06826647
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2020-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03895372
The ClinicalTrials.gov registry entry for NCT03895372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-06826647 or Placebo is the first listed.
NCT03895372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03895372 about?
NCT03895372 is a clinical study titled "A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis". This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosi...
What is the current status of trial NCT03895372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2019-06-27. Estimated completion is 2020-11-26.
What interventions are being tested in trial NCT03895372?
The interventions under investigation include: PF-06826647 or Placebo (DRUG), PF-06826647 (DRUG).
Who is sponsoring clinical trial NCT03895372?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.